Wedbush cuts Beam Therapeutics' target price to $28 from $65
BEAM•Wedbush cut its target price for Beam Therapeutics to $28 from $65.
Related News
Trinseo adjourns annual shareholder meeting to November 20, 2026
TSE•
Terradot and HASI close $34 million investment for carbon removal projects
HASI•
Qatar says Iran needs to show good intentions for mediation efforts to succeed
USO•
Fed feast: Consumer confidence, durable goods, new home sales, and more
SPY•
Oil falls as Middle East talks outweigh concern over fresh strikes
USO•